-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the Chilean Ministry of Health announced the real-world data of the inactivated vaccine CoronaVac developed by Beijing Sinovac Biotechnology Co.
Kerlaifu is an inactivated COVID-19 vaccine jointly developed by Kexing.
▲The situation of new crown vaccination in Chile (picture source: reference [2])
An analysis of real-world COVID-19 infection data from February 2 to April 1 this year shows that after two doses of Kellyford vaccination are completed 28 days apart, the effectiveness of the vaccine to prevent symptomatic COVID-19 reaches 67% , The effectiveness of preventing hospitalization reached 85%, the effectiveness of preventing entry into the intensive care unit (ICU) was 89%, and the effectiveness of preventing death was 80%.
▲Summary of the effectiveness of Kerlaifu in preventing COVD-19 (picture source: reference [2])
In addition, this study also demonstrates the importance of complete two-dose vaccination.
They found that in terms of preventing symptomatic COVID-19, the protective effect of Kellyford in some vaccinated populations was only 16.
Dr.
Reference materials:
[1] China's Sinovac COVID-19 vaccine 67% effective in preventing symptomatic infection-Chile govt report.
[2] Estudio sobre Sinovac realizado en Chile arrojó un 80% de efectividad para prevenir la muerte.
[4] Chile Says Sinovac Is 80% Effective Against Death From Covid.